KX2-391 has Entered into Phase 1b Clinical Trial for AML

Kinex Pharmaceuticals has announced that its oncology drug, KX2-391, has entered a clinical trial entitled “A Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy”. This compound is a dual Src kinase/tubulin polymerization inhibitor that has previously been evaluated in a Phase 1 study.

The study commenced in July 2011 at Roswell Park Cancer Institute (RPCI) in Buffalo, New York and Thomas Jefferson University in Philadelphia, Pennsylvania and is currently recruiting patients.

This study has been designed to determine the Recommended Phase 2 Dose of KX2-391 when administered once-daily. The trial will evaluate safety, tolerability and pharmacokinetics. An exploratory biomarker for target inhibition will also be evaluated.

For more information on this study, visit www.clinicaltrials.gov